Guest Editors
Prof. Dr. Po-Kai Chuang
Email: pokaipkc@g-mail.nsysu.edu.tw
Affiliation: Institute of Biomedical Sciences, National Sun Yat-Sen University, 804201, Kaohsiung, Taiwan
Homepage:
Research Interests: drug resistant, glycobiology, oncology research
Summary
This special issue of Oncology Research focuses on the rapidly evolving landscape of targeted cancer therapy, highlighting three critical areas: novel small molecule drugs, advances in inhibitor technologies, and strategic drug repurposing for cancer treatment.
The issue explores breakthrough advances in small molecule drug design, including next-generation kinase inhibitors, allosteric modulators, and epigenetic regulators. Special attention is given to innovative inhibitor mechanisms, including small molecule inhibitors, proteolysis-targeting chimeras (PROTACs), and selective degraders that target previously undruggable proteins.
Additionally, this collection examines drug repurposing, where existing FDA-approved medications are strategically repositioned for oncological applications. This approach offers significant advantages including reduced development timelines, established safety profiles, and cost-effective pathways to clinical implementation.
The special issue welcomes original research articles, comprehensive reviews, clinical studies, and translational research that address:
• Novel Small Molecule Development: Structure-based drug design, fragment-based approaches, and computer-aided drug discovery
• Advanced Inhibitor Technologies: Covalent inhibitors, allosteric modulators, protein degraders (PROTACs), and molecular glues
• Drug Repurposing Strategies: Systematic approaches to identifying and validating existing drugs for cancer applications
• Precision Medicine Applications: Biomarker-driven patient selection and resistance mechanisms
• Clinical Translation: Early-phase clinical trials, pharmacokinetic studies, and real-world evidence
• Regulatory Pathways: Mechanical processes, accelerated pathways, and regulatory considerations for anticancer drugs
Keywords
Small molecule drugs, Drug repurposing, Targeted therapy, Combination therapy, Structure-based drug design, proteolysis-targeting chimeras (PROTACs), Computer-aided drug design, Targeted Biomarkers, Resistance mechanisms, Metabolic pathway inhibitors, Cell growth suppression, Cell cycle arrest, Signal transduction, Cancer stem cells, Metastasis inhibition, Lectin-carbohydrate interactions
Login
Register
Submit a Paper
Propose a Special lssue